Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor.
Level 5 - mechanism / opinion, no new human data
Narrative review of genetic mechanisms and clinical management in monogenic versus polygenic hypercholesterolemia
PubMed 33343620 · doi:10.3389/fgene.2020.554931
What was done
This narrative review synthesized the genetic architecture, cardiovascular risk profiles, screening recommendations, and treatment strategies comparing monogenic familial hypercholesterolemia (associated with variants in LDLR, APOB, PCSK9, or ApoE) against polygenic hypercholesterolemia driven by cumulative small-effect single nucleotide variants.
What was found
The abstract reports clinical definitions (severe hypercholesterolemia defined as LDL-C >95th percentile or >190 mg/dl) and treatment goals (LDL-C <100 mg/dl or a >=50% reduction for primary prevention). Monogenic familial hypercholesterolemia is characterized as conveying the highest cardiovascular risk, followed by polygenic forms. Genetic cascade screening is recommended for first- and second-degree relatives in monogenic disease, whereas lipid screening in first-degree relatives is recommended for other forms due to a lack of diagnostic consensus for polygenic disease. No empirical cohort data or effect size numbers are provided in the abstract.
Why it matters
It outlines practical clinical distinctions between single-gene and polygenic hypercholesterolemia, guiding appropriate family screening strategies and LDL-C reduction targets.
Limits
The abstract describes a narrative review without systematic search parameters, quantitative risk estimates, or primary patient data. Diagnostic criteria and precise prevalence figures for polygenic hypercholesterolemia remain unestablished.
Cited by
- supports Cardiovascular and lipid guidelines establish an LDL cholesterol level of 190 mg/dL or greater as a threshold mandating clinical intervention and statin therapy, often driven by underlying genetic conditions such as LDL receptor abnormalities.